Physician profile
Darrell J Solet
NPI 1770550808
$81,369.11
in general payments reported to CMS, 2019-2025
35 companies · $4,833 in 2025
The $4,833 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,033 · 2020: $5,336 · 2021: $21K · 2022: $20K · 2023: $11K · 2024: $15K · 2025: $4,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $8,762 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,250 · Food and Beverage: $5,583 · Education: $57.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,608.29 |
| Travel and Lodging | $8,761.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,250.00 |
| Food and Beverage | $5,583.13 |
| Education | $57.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $67,848.55 | 2019-2025 | Mitraclip, Triclip, Amplatzer Amulet |
| Edwards Lifesciences Corporation | $4,853.33 | 2024-2025 | Pascal, Evoque |
| Ancora Heart, INC. | $1,338.33 | 2019 | |
| Medtronic Vascular, INC. | $1,256.65 | 2019 | |
| Amgen INC. | $862.23 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $786.53 | 2019-2025 | |
| Pfizer INC. | $534.35 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $461.33 | 2019-2024 | Xarelto |
| Medtronic, INC. | $408.86 | 2023-2025 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals Lp | $385.11 | 2020-2025 | Farxiga, Brilinta |
| Amarin Pharma, INC. | $317.01 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $293.53 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $275.44 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.83 | 2020-2025 | Jardiance |
| Abiomed | $200.11 | 2024-2025 | Impella |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Solet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.